Eli Lilly’s (LLY) neuroscience franchise includes neuroscience products Cymbalta, Strattera, and Zyprexa.
The above chart shows revenues for Eli Lilly’s neuroscience drugs over the last few quarters.
Strattera, a drug for attention-deficit/hyperactivity disorder, reported a 17.0% fall in revenues to $186.6 million in 2Q17 compared to $224.6 million in 2Q16. US sales fell 29.0% to $101.5 million, while sales outside the US markets rose 5.0% to $85.1 million in 2Q17.
Cymbalta, an antidepressant for the treatment of depression and anxiety and, at times, for bone and muscle pain, reported a 13.0% fall in revenues to $206.6 million in 2Q17 compared to $236.5 million in 2Q16. The fall in revenues was driven by a 22.0% fall in US sales to $47.1 million and a 9.0% fall in sales outside the US markets to $159.6 million in 2Q17.
Zyprexa, an antipsychotic drug for the treatment of brain disorders such as schizophrenia, reported a 33.0% fall in revenues to $140.8 million in 2Q17 compared to $210.7 million in 2Q16. US sales fell 10.0% to $13.0 million, while sales outside the US markets fell 35.0% to $127.8 million in 2Q17. Sales outside the US markets were impacted by patent expiration in Japan in June 2016 with a 56.0% fall in sales in Japan due to generic competition.